ADM Therapeutics

ADM Therapeutics is a French biotechnology company dedicated to developing disease-modifying therapies for Alzheimer's disease and other tauopathies. Spun out from the University of Lille and Inserm, the company focuses on a novel pharmacological approach to inhibit the pathological aggregation of the Tau protein. Their lead program involves small molecule inhibitors designed to stabilize Tau in its physiological state, preventing the formation of neurotoxic tangles. By targeting the early stages of protein misfolding, ADM Therapeutics aims to provide a more effective intervention for neurodegenerative disorders than current symptomatic treatments.